= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Marshall

MSACL 2018 EU Abstract

Topic: Endocrinology

Podium Presentation in the Ether on Wednesday at 9:20 (Chair: Flaminia Fanelli)

Quantification of Testosterone, Androstenedione and 17-Hydroxyprogesterone Collected Using Mitra Micro Sampling Devices

David Marshall (Presenter)
Manchester University NHS Foundation Trust

Presenter Bio(s): I am a trainee Clinical Scientist at Wythenshawe Hospital in Manchester. I have worked with clinical mass spectrometry for the last 3 years, including routine operation, method development and troubleshooting. I am also in the process of completing a Masters in Clinical Science as part of my training

Authors: David Marshall, Brian Keevil
Manchester University NHS Foundation Trust


Mitra devices are small polymer tips that absorb a fixed amount of blood which can be dried prior to analysis.

A simple liquid:liquid extraction was used following reconstitution of the mitra device in distilled water. Separation was carried out using a Waters Acquity HSS T3 column which resolved the peaks well.

We have developed an assay for the simultaneous quantification of testosterone, androstenedione and 17-hydroxyprogesterone using a single mitra tip.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: